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Abstract: Alternative splicing of pre-mRNA allows the generation of multiple splice isoforms from
a given gene, which can have distinct functions. In fact, splice isoforms can have opposing functions
and there are many instances whereby a splice isoform acts as an inhibitor of canonical isoform
function, thereby adding an additional layer of regulation to important processes. Angiogenesis is
an important process that is governed by alternative splicing mechanisms. This review focuses on
the alternative spliced isoforms of key genes that are involved in the angiogenesis process; VEGF-A,
VEGFR1, VEGFR2, NRP-1, FGFRs, Vasohibin-1, Vasohibin-2, HIF-1α, Angiopoietin-1 and Angiopoietin-2.
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1. Alternative Splicing
The human genome consists of an estimated 20,000 protein-coding genes [1], which can give rise
to a much greater number of proteins. Alternative splicing is one of the main processes that accounts
for the increased protein to gene ratio. In fact, alternative splicing is reported to be responsible for
40% of protein modifications [2]. It involves the formation of multiple mRNA products from a single
pre-mRNA, and many of these mRNA products are then translated into proteins that may have distinct
structures or functions [3]. This important process therefore increases the coding capacity of a given
gene, and as it has been reported that more than 95% of pre-mRNAs are alternatively spliced in
mammals [4], research into alternative splicing has gathered momentum over the past two decades.
Alternative splicing is heavily regulated. However, like most biological processes, alternative splicing
is open to faults, which can result in disease. It has been suggested that around 33% of mutations that
cause disease affect splicing [5].
1.1. The Splicing Reaction
Splicing of pre-mRNAs involves the excision of introns and joining together of exons, which
forms the mature mRNA transcript that is then translated into protein [6]. This is achieved by the
spliceosome, which is a macromolecule structure comprised of five small nuclear ribonucleoprotein
particles (snRNPs) and over 100 proteins [7].
The splicing reaction occurs in multiple stages, as outlined in Figure 1. Briefly, the CAG GURAGU
consensus sequence at the 5′ of the intron is bound by the U1 snRNP, whilst SF1 binds to the branch
point sequence YNYURAC, and the 35kDa U2AF subunit (U2AF35) binds to the 3′ splice site via an AG
dinucleotide. In addition, the downstream polypyrimidine sequence of the branch point is bound by the
U2AF65 subunit. The U2 snRNP displaces the SF1 protein at the branch point sequence. Following this,
the U5.U4/U6 tri-snRNP is recruited to the U1 snRNP, and the NineTeen Complex (NTC) connects to
the spliceosome. After conformational and compositional rearrangements, the catalytic function of the
spliceosome is activated, and a transesterification reaction occurs. This releases the U1 and U4 snRNPs
and forms an intron lariat at the 3′ part of the exon. A further transesterification reaction at the 3′ splice
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site releases the 3′ exon, which leads to exon ligation and excision of the lariat containing U4, U5 and U6
snRNPs. The spliced mature mRNA transcript can then be translated into protein [7,8].
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Figure 1. The splicing reaction. U1 snRNP binds to the CAG GURAGU consensus sequence, SF1 binds 
to the branch point sequence and U2AF35 binds to the 3′ splice site. The downstream polypyrimidine 
sequence of the branch point is bound by the U2AF65 subunit. SF1 is displaced by U2 and the U5. 
U4/U6 tri-snRNP is recruited to U1. Conformational and compositional rearrangements occur, which 
results in the release of U1 and U4, the addition of the NineTeen Complex (NTC), and the first 
transesterification reaction. A second transesterification reaction occurs which releases the lariat. 
Exons are ligated together and continue to translation. Introns are degraded and snRNPs are 
reprocessed for other splicing reactions. 
1.2. Regulation of Alternative Splicing 
Alternative splicing arises when exons or introns are either included or excluded from a mature 
mRNA transcript. The major alternative splicing patterns (exon skipping, intron retention, mutually 
exclusive exons and alternative 3′ or 5′ splice sites) are illustrated in Figure 2, which forms through 
the recognition of short cis-acting splicing regulatory elements (SREs) by trans-acting splice factors or 
RNA binding proteins (RBPs). SREs are categorised depending on where in the pre-mRNA the RNA 
binding protein is binding (exon or intron), and whether they enhance or inhibit splicing. This forms 
four subgroups of SREs; exonic splicing enhancers (ESEs), intronic splicing enhancers (ISEs), exonic 
splicing silencers (ESSs) and intronic splicing silencers (ISSs).  
RBPs recognise particular SREs and determine which sections of pre-mRNA are included in the 
mature transcript. Therefore, the regulation of alternative splicing can be influenced by the amount 
and activity of RBPs, the two main studied groups of which are serine/arginine rich (SR) proteins (12 
discovered to date [9]) and heterogenous nuclear ribonucleoproteins (hnRNPs) (23 discovered to date 
[10]). Originally, it was thought that SR proteins bind to ESEs and promote exon inclusion, whereas 
spliceosome access to the polypyrimidine tract is blocked by hnRNPs, thereby promoting exon 
exclusion [11]. For example, hnRNP H/F has been shown to bind to exon 18b regulatory sequences of 
T-cell factor-3, which represses the inclusion of exon 18b and results in an increase in the E12 isoform 
that contains exon 18a instead of exon 18b [12]. However, instances whereby SR proteins promote 
exon exclusion and hnRNP proteins promote exon inclusion have since been reported [13–16]. In 
addition, it has been reported that SR proteins and hnRNPs are antagonists of each other when 
binding to SREs [17]. Therefore, changes in the ratio of SR protein to hnRNPs in the nucleus can alter 
splicing.  
Figure 1. The splicing reaction. U1 snRNP binds to the CAG GURAGU consensus sequence, SF1 binds
to the branch point sequence and U2AF35 binds to the 3′ splice site. The downstream polypyrimidine
sequence of the branch point is bound by the U2AF65 subunit. SF1 is displaced by U2 and the U5. U4/U6
tri-snRNP is recruited to U1. Conformational and compositional rearrangements occur, which results in
the release of U1 and U4, the addition of the NineTeen Complex (NTC), and the first transesterification
reaction. A second transesterification reaction occurs which releases the lariat. Exons are ligated
together and continue to translation. Introns are degraded and snRNPs are reprocessed for other
splicing reactions.
1.2. Regulation of Alternative Splicing
Alternative splicing arises when exons or introns are either included or excluded from a mature
mRNA transcript. The major alternative splicing patterns (exon skipping, intron retenti n, mutually
exclusive exons and alternative 3′ or 5′ li e sites) are illustrated in Fi ure 2, which forms through
the recognition of short cis-acting splicing regulatory elements (SREs) by trans-acting splice fact rs or
RNA binding proteins (RBPs). SREs are categorised depending on where in the pre-mRNA the RNA
binding protein is binding (exon or intron), and whether they enhance or i hibit splicing. This forms
four subgr ups of SREs; exonic splicing enhancers (ESEs), intronic splicing enhancers (ISEs), exonic
splicing silencers (ESS ) and introni splicing silencers (ISSs).
RBPs re ognise particular SREs and determi e which ections of pre-mRNA are included in the
mature transcript. The efore, the regulation of alt rnative splici g can be influenced by th amount
and activity of RBPs, the two main studied groups of which are serine/argini e rich (SR) protei s
(12 discovered to date [9]) and heterog nous nuclear ribonucleoproteins (hnRNPs) (23 discovered
to dat [10]). Originally, it was thought that SR pr teins bind to ESEs and promote exon inclusion,
whereas spliceosome access to the polypyrimidine tract is blocked by hnRNPs, thereby promoting exon
exclusion [11]. For example, hnRNP H/F has been hown to bind to exon 18b regulatory sequences of
T- ell factor-3, which re r sses the inclusion of exon 18b and results in an incr ase in the E12 isoform
that contains exon 18a instead of exo 18b [12]. However, i stances whereby SR proteins promote exon
exclusion and hnRNP pro ins promote exon inclusion have since been r ported [13–16]. In addition,
it has been reported that SR proteins and hnRNPs are antagonists of each oth r when binding to
SREs [17]. T erefore, changes in the ratio of SR protein to hnRNPs in the nucleus can alter splicing.
Int. J. Mol. Sci. 2019, 20, 2067 3 of 27
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  3 of 27 
 
 
Figure 2. Different alternative splicing mechanisms; exon skipping, mutually exclusive exons, 
alternative polyadenylation sites, intron retention, alternative 5′ or 3′ splice sites and alternative 
promoters. The coloured splicing patterns correspond to the coloured arrows. 
The SR proteins SRSF1, SRSF2 and SRSF6 are involved in the regulation of the spliceosome itself. 
They promote the binding of the U1 and U2 snRNPs to the 5′ and 3′ splice sites, respectively [18]. 
Therefore, the binding of SR proteins to SREs is highly regulated through phosphorylation activation 
by SR protein kinases, such as CDC-like-kinase 1 (CLK1) and SRSF-protein-kinase 1 (SRPK1). For 
instance, an established pathway for SRSF1-mediated splicing involves phosphorylation of SRSF1 by 
SRPK1, which facilitates the binding of SRSF1 to a transportin protein (Tr-SR) and results in the 
nuclear import of SRSF1 [19]. Once in the nucleus, SRSF1 is stored as nuclear speckles, and 
subsequent hyper-phosphorylation by CLK1 releases SRSF1 from nuclear speckle storage and allows 
SRSF1 to bind to SREs on pre-mRNA for the splicing reaction [20]. In addition to the major alternative 
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[21]. This results in the premature cutting of the pre-mRNA by cleavage factors and the addition of 
the poly-A tail to the truncated pre-mRNA, which produces the soluble VEGFR-1 (sVEGFR-1) isoform 
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2. Angiogenesis 
Angiogenesis is an important process that is defined as the formation of new blood vessels from 
pre-existing vasculature. It is vital during embryonic development, wound healing, hair growth, and 
reproduction [22]. However, dysregulation of angiogenesis is associated with a range of pathologies 
in adults, such as cancer, diabetic retinopathy, rheumatoid arthritis and endometriosis [23,24]. This 
has led to the study of complex signalling pathways that regulate angiogenesis.  
Angiogenic Vessel Formation 
The angiogenesis process is activated by pro-angiogenic signals, such as vascular endothelial 
growth factor-A (VEGF-A), angiopoietin-2 (ANG-2) and fibroblast growth factor (FGF) [25]. Ang-2 
and matrix metalloproteinases (MMPs) mediate the detachment of pericytes from the vessel wall. 
This causes the loosening of junctions that are between the endothelial cell monolayer and the nascent 
vessel dilates. VEGF-A, which is the most extensively investigated member of the VEGF family, 
increases endothelial cell layer permeability which forces plasma proteins out of the blood vessels 
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ro osed whereby demethylated hnRNP D is unable to bind to ARE intron
13 [21]. This results in the premature cutting of the pre-mRNA by cle vage factors and the addition
of the poly-A ail to the truncated pre-mRNA, which produces the soluble VEGFR-1 (sVEGFR-1)
isoform [21]. How ver, when hnRNP D is methylated, it binds to ARE in intron 13 and causes the
splicing out of the intron, which produc s the membrane-bou d can nical isoform of VEGFR-1 [21].
2. Angiogenesis
Angiogenesis is an i portant process that is defined as the for ation of new blood vessels fro
pre-existing vasculature. It is vital during e bryonic develop ent, wound healing, hair growth, and
reproduction [22]. However, dysregulation of angiogenesis is associated with a range of pathologies in
adults, such as cancer, diabetic retinopathy, rheumatoid arthritis and endometriosis [23,24]. This has
led to the study of complex signalling pathways that regulate angiogenesis.
Angiogenic Vessel Formation
The angiogenesis process is activated by pro-angiogenic signals, such as vascular endothelial
growth factor-A (VEGF-A), angiopoietin-2 (ANG-2) and fibroblast growth factor (FGF) [25]. Ang-2
and matrix metalloproteinases (MMPs) mediate the detachment of pericytes from the vessel wall.
This causes the loosening of junctions that are between the endothelial cell monolayer and the nascent
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vessel dilates. VEGF-A, which is the most extensively investigated member of the VEGF family,
increases endothelial cell layer permeability which forces plasma proteins out of the blood vessels and
into the surrounding tissue, where they form an extracellular matrix scaffold for the attachment of
endothelial cells. The formation of the vascular sprout is guided by the tip cell (stimulated by VEGF-A
receptors, neuropilins, Delta-like 4 (DLL4) and JAGGED1 (JAG1), and the elongation of the stalk is
facilitated by neighbouring stalk cells (stimulated by NOTCH, NOTCH regulated Ankyrin repeat
protein (NRARP), wingless/integrateds (WNT)s, placental growth factor (PIGF) and fibroblast growth
factors (FGFs)) [26]. Recently, the macrophage stimulating-1/Forkhead box protein O1 (MST1/FOXO1)
cascade was identified to direct the migration of tip cells towards hypoxic regions [27]. The vascular
lumen is then established and this is mediated by a variety of factors including: vascular endothelial
cadherin (VE-cadherin), CD34, sialomucins, VEGF-A and hedgehog ligands. Following this, the cells
become covered in pericytes, which is signalled by the expression of factors, such as platelet-derived
growth factor-β (PDGF-B), angiopoietin-1 (ANG-1), transforming growth factor-β (TGF-β), ephrin-B2
and NOTCH. The basement membrane is reformed through the inhibition of MMPs by a tissue
inhibitor of metalloproteinases (TIMPs) and plasminogen activator inhibitor-1 (PaI-1), which results
in the maturation of the vessel [26]. The important process of angiogenesis is highly regulated at
many levels, including transcriptional [28,29], post-transcriptional [30], microRNAs [30,31], allosteric
enhancement [32], and as discussed in this review, alternative splicing. Many genes involved in
angiogenesis have been shown to be alternatively spliced, and there are many instances whereby
isoforms negatively regulate the canonical isoform (Figure 3). This review will discuss current known
splicing events that occur in genes associated with angiogenesis and the functions of their splice
isoforms (if known) as shown in Table 1. The major splicing events are shown in Figure 4.
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Table 1. Splice isoforms of key angiogenic genes and their known functions.
Gene Splice Variants Function
VEGF-A
VEGF-A111 Proangiogenic. Diffusible [33,34]
VEGF-A121 Proangiogenic. Diffusible. Implicated in tumorigenesis [33,35,36]
VEGF-A145 Proangiogenic. Bind to cell surface and extracellular matrix [33,34]
VEGF-A165 Proangiogenic. Moderately diffusible. Implicated in tumorigenesis [33,36]
VEGF-A189 Proangiogenic. Implicated in tumorigenesis [33,36,37]
VEGF-A206 Proangiogenic. Strongly bind to cell surface and ECM [33,37]
VEGF-A183 Proangiogenic [33]
VEGF-Axxxb
Anti-angiogenic. Downregulated in cancer, diabetic retinopathy, Denys Drash syndrome, retinal vein occlusion.
Upregulated in systemic sclerosis and asthma [33,38]
VEGFR1 sVEGFR1 Potent anti-angiogenic [39]
VEGFR2
sVEGFR2 Decreases lymphangiogenesis. Downregulated in neuroblastoma [39]
esVEGFR2 Decreases lymphangiogenesis [39]
NRP-1
s11NRP1, s12NRP1, sIIINRP1, sIVNRP1 Soluble isoform. Antagonists of NRP1 signalling. Anti-angiogenic and anti-tumorigenic [40]
NRP1-∆E16 No functional difference to full length NRP1 [41]
NRP1∆7 Affects glycosylation status of NRP1. Anti-tumorigenic in prostate cancer and breast cancer cells [42]
FGFRs
IIIb EMT. Found in epithelial tissues. Evidence as a tumour suppressor and as a tumour promoter [43,44]
IIIc EMT. Found in mesenchymal tissues. Tumourigenic [43]
FGFRα Contains autoinhibitory IgI domain which results in a lower affinity for FGFs and decreased signalling comparedto FGFRβ [45,46]
FGFRβ Higher affinity for FGFs and enhanced signalling. Increases proliferation and linked to tumourigenesis [43,45,46]
Soluble receptors Can be found in locations in the cell other than the cell membrane. Precise function unknown [43,45]
C1, C2 and C3 C3 has the most transforming activity, C2 has moderate transforming activity and C1 has the least transformingactivity. C3 implicated in oncogenesis [47]
Deletion of the VT motif Prevention of binding of some effector molecules. Suggested to be unable to activate the downstream Ras/MAPKsignalling pathway [48]
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Table 1. Cont.
Gene Splice Variants Function
Vasohibin-1 VASH1A and VASH-1B Both are anti-angiogenic. VASH-1A promotes normalisation of abnormal tumour blood vessels. VASH-1B prunesvasculature [49,50]
Vasohibin-2
355aa Predominantly expressed in HUVECs. Function unknown [51]
290aa Anti-angiogenic activity [52]
311aa, 156aa, 117aa, 104aa Function unknown
HIF-1α
HIF-1α∆11 Promotes tumorigenesis through enhancement of HIF activity [52]
HIF-1α∆12 and HIF-1α∆11&12 Inhibits dimerisation of HIF-1α and HIF-1β. Act as dominant regulators of HIF-1 transcription [53]
HIF-1α∆14 Less potent activator of HIF-1 transcription than canonical form of HIF-1α [54]
HIF-1α417 Amplifies HIF-1β-mediated transcription of EPO gene [53]
HIF-1TAG Function unknown
HIF-1α Alt1 Function unknown
HIF-3α
IPAS Dimerises with HIF-α subunits but cannot initiate transcription of HIF target genes, such as VEGF. Dampensangiogenesis [53,55,56]
HIF-3α4 Forms complex with HIF-1α and prevents HIF transcription. Hampers angiogenesis and proliferation [55]
Ang-1 1.5 kb, 1.3 kb Bind to Tie-2 and induce its autophosphorylation [57]
0.9 kb, 0.7 kb Bind to Tie-2 but do not induce its autophosphorylation [57]
Ang-2 Ang-2B Not precise function but indication of inactivation of the vasculature and vascular remodelling [58]
Ang-2443 Antagonist of Tie-2 signalling activation. Suggestive role in the regulation of inflammatory processes [59]
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3. Splicing in Angiogenesis
3.1. Vascular Endothelial Growth Factor-A (VEGF-A)
The binding of VEGF-A to VEGF receptor 2 (VEGFR2) is considered to be the main stimulatory
signal of angiogenesis in vivo [60]. Studies have shown that VEGF-A is secreted by many different
cell types, including: endothelial cells, fibroblasts, smooth muscle cells, platelets, neutrophils and
macrophages [34]. VEGF-A is produced by 60% of tumours [61] and has therefore been extensively
investigated for anti-cancer therapeutics.
The VEGF-A mRNA contains eight exons, the splicing of which gives rise to a variety of isoforms.
The six major isoforms of VEGF-A are: VEGF-A111, VEGF-A121, VEGF145, VEGF-A165, VEGF-A189
and VEGF-A206 (where the subscripted numbers denoted the number of amino acids present in
the isoform) [34]. Additionally, another less commonly expressed isoform has also been reported,
known as VEGF-A183 [62]. The bioavailability of the isoforms is governed by a mRNA sequence
that spans exons 6a and 7 determines the binding capacity of the isoforms to heparin and heparin
sulphate proteoglycans that are located on the cell surface and extracellular matrix [34,63]. VEGF-A145,
VEGF-A189 and VEGF-A206 strongly bind to both the cell surface and extracellular matrix, whereas
VEGF-A111 and VEGF-A121, which both lack exons 6 and 7, are readily diffusible [35–37]. VEGF-A165
is moderately diffusible with an estimated 50–70% being bound to the cell surface or extracellular
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matrix following secretion [35]. VEGF-A165 is the most abundantly expressed isoform and most potent
initiator of angiogenesis [63]. In fact, VEGF-A189 has less angiogenic activity when compared to the
VEGF-A165 and VEGF-A121 isoforms [64,65]. In addition, VEGF-A165 has increased mitogenic effects in
comparison to VEGF-A189, which is caused by its heparin binding ability that allows the attachment to
the neuropilin co-receptor [66].
It is hypothesized that many splice factors and signaling pathways are involved in the regulation
of VEGF-A isoform expression. Indeed, CAPER-α, a transcriptional coactivator for steroid receptors
has been shown to alter the ratio of VEGF-A189 to VEGF-A165 in Ewing cells [67]. Furthermore,
an earlier study also showed that siRNA knockdowns of CAPER-α increased the VEGF-A121/VEGF-A189
expression ratio in breast cancer cells [68]. Therefore, it can be concluded that CAPER-α is involved
in the regulation of alternative splicing of these three isoforms of VEGF-A, and it is proposed that
perhaps CAPER-α may also govern the selection of other VEGF-A isoforms. An additional layer of
VEGF-A regulation has been uncovered, whereby microRNAs (particularly miRNA-297 and -299 in
tumour-associated macrophages; and miR-574-3p in human myeloid cells) bind to the CA-rich element
(CARE) in the 3′ UTR of VEGF-A, which results in the negative regulation of VEGF-A expression [69,70].
However, upon hypoxic insult, heterogenous nuclear ribonucleoprotein L (hnRNP L) is translocated
from the nucleus to the cytoplasm, where it can interact with VEGF-A mRNA. More specifically, hnRNP
L binds to CARE, thereby inhibiting the binding of the microRNAs to the sequence and subsequently
induces the splicing of VEGF-A [69]. In addition, it has been shown that increased hnRNP L binding
to the CARE element during hypoxia also reduces the binding of the GAIT complex to the GAIT
element, which accordingly results in decreased translational repression of VEGF-A [71]. However,
whether these mechanisms induce splicing for the expression of a certain isoform of VEGF-A is yet to
be determined.
Almost 20 years ago, another family of VEGF-A isoforms was discovered, which arise from
alternative splicing of exon 8 (Figure 4A). The isoforms have the same number of amino acids, but
alternative sequences in the C terminus [72]. So far, four alternative VEGF-AXXXb isoforms have been
identified: VEGF-A165b, VEGF-A121b, VEGF-A189b, and VEGF-A145b [72–75]. It is generally accepted
that the VEGF-Axxxb family of isoforms are inhibitors of angiogenesis, and the VEGF-Axxxa family
promotes angiogenesis (Figure 3B), which arguably makes them the most intriguing splicing event of
VEGF-A. In fact, it has been reported that VEGF-Axxxb expression is downregulated in cancer, diabetic
retinopathy, Denys Drash syndrome and retinal vein occlusion, and upregulated in systemic sclerosis
and asthma [38].
The aberrant splicing of VEGF-A exon 8 has been extensively investigated, and a few different
signalling pathways have been reported to be involved in the production VEGF-Axxxb. In the first
pathway, stimulation by growth factors (e.g., insulin growth factor (IGF)) promotes the phosphorylation
of SRSF1 by SR protein kinase 1, which allows transportation of SRSF1 into the nucleus. SRSF1 then
binds with the proximal splice site of exon 8 and results in the production of the VEGF-Axxxa isoform [76].
However, knockdown of SRSF1 and knockdown and inhibition of SRPK1 altered the splicing of VEGF-A
mRNA to produce more of the VEGF-Axxxb isoform, and so it is thought that VEGF-Axxxb production
is linked to the inhibition of this pathway [77].
The other three pathways described so far involve the selection of the distal splice site of VEGF-A
exon 8, which results in production of the VEGF-Axxxb isoform. One pathway involves the stimulation
of CLK1/4 phosphorylation of SRFS6 by TGF-β, which leads to distal splice site selection of VEGF-A
exon 8 [78,79]. The remaining two pathways that have been uncovered to date involve VEGF-Axxxb
splice site selection by SRSF2. One such pathway includes the wingless integrated 5a/orphan receptor
tyrosine kinase-like receptor-2/Jun N-terminal kinase (Wnt5a/Ror2/JNK) dependent mechanism [80],
and the other pathway involves E2F1 [81].
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3.2. Vascular Endothelial Growth Factor Receptors (VEGFRs)
In order to facilitate a cellular response, a VEGF-A dimer binds to paired tyrosine kinase receptors,
named vascular endothelial growth factor receptors (VEGFRs), which have been found in a range
of cell types, such as endothelial cells [82], haematopoietic [83] and smooth muscle cells [84]. There
are three types of VEGFRs: VEGFR1, VEGFR2 and VEGFR3, which are encoded by different genes;
however, VEGFR1 and VEGFR2 share similar structures [85,86]. The VEGF-A family of isoforms
bind to VEGFR1 and VEGFR2 to facilitate angiogenesis, whereas VEGFC/D isoforms bind to VEGFR3
to drive lymphangiogenesis for the formation of lymph vessels [87]. VEGFR1 has decreased kinase
activity when compared to VEGFR2, despite having a higher affinity for the binding of VEGF-A, and
so is highly regarded as a decoy receptor [88,89]. Therefore, most research into the roles of VEGFRs in
angiogenesis have focused on VEGFR2.
An additional step is required to activate VEGFR2 signalling after VEGF-A has bound to the
receptor. The binding of allosteric sites of VEGFR2 are necessary to cause a conformational twist of the
receptor, which leads to its activation [34]. Similar structural arrangements are caused by VEGF-A165,
VEGF-A165b and VEGF-A121, which ultimately allows the transduction of the signal [90]. VEGF-A165
has been shown to activate phosphorylation of VEGFR2, AKT and ERK the most, whereas VEGF-A165b
activation of VEGFR2 results in diminished stimulation of angiogenesis [91–93], and it is for this reason
the ‘anti-angiogenic’ label has been applied to VEGF-A165b. Most evidence points to a partial agonistic
function for VEGF-A121 [93,94]; however, there have also been some cases where VEGF-A121 has shown
full agonistic qualities. For example, several independent groups have shown that VEGF-A121 activation
induced phosphorylation of VEGFR2, but at a reduced rate to VEGF-A165a [95–97]. In addition, when
compared to VEGF-A165, VEGF-A121 generated less motility and sprouting in human umbilical vein
endothelial (HUVEC) cells [95]. Studies into the effect of VEGF-A121 on ex-vivo angiogenic sprouting and
vascular permeability have demonstrated VEGF-A121 to have both equal and lower levels of generation
to VEGF-A165 [34].
VEGFR2 signalling is complicated further by splicing of VEGFR2. Endogenous soluble VEGFR2
(esVEGFR2) [39] arises from partial retention of intron 13 and a consequential early termination stop
codon. The resultant protein contains six out of the seven extracellular immunoglobulin-like domains
and has a unique c-terminal sequence that does not exist in the canonical form of VEGFR2. It can be
noted that there is another soluble variant of VEGFR2 which is formed through proteolytic shedding
from the cell surface, which is a post-translational modification and is not formed from alternative
splicing of VEGFR2 [98]. Both of these variants act on the lymphangiogenic system through trapping of
VEGF-C, which obstructs the activation of VEGFR3, resulting in the decrease of lymphatic endothelial
cell proliferation [98]. Lymphangiogenesis in tumours promotes metastasis of malignant cancer cells.
In accordance with this, researchers have observed a correlation between sVEGFR2 downregulation
and progression of malignant neuroblastoma, which suggests a protective function for these variants
in malignancies [39]. Another truncated VEGFR2 isoform has been discovered in rat retina, which
contains the entire extracellular domain and a part of the intracellular domain. Little is known about
this isoform; however, it has confirmed VEGF-A activity and leads to increased cytoplasmic calcium
and therefore is thought to be functional in the angiogenic system [99].
Although VEGFR1 is heavily regarded as a ‘decoy’ receptor for angiogenesis, it has been implemented
in tumour progressive processes. In adults, VEGFR1 has been shown to activate inflammation, tumour
growth, metastasis; increase chemotaxis of monocytes and has been linked to increased release of
MMP9 from human vascular smooth muscle cells [99,100]. To date, four alternatively spliced variants of
VEGFR1 have also been discovered: sVEGFR1-i13 (shown in Figure 4A), sVEGFR1-i14, sVEGFR1-e15a
and sVEGFR1-e15b [101–103]. The sVEGFR1-i13 and sVEGFR1-i14 isoforms have extensions beyond exon
13 and exon 14, respectively, whereby sVEGFR1-i13 arises from an extended read through of a potential
splice site in exon 13 (Figure 4A), and sVEGFR1-i14 arises from a skipped splice site. The sVEGFR1-e15a
and sVEGFR1-i15b isoforms arise from the inclusion of an alternative exon in place of exon 15 (either
exon 15a or 15b) [102,103]. Membrane-bound VEGFR1 and the soluble isoforms share the first 13 exons,
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which code for the first six N-terminal immunoglobulin-like domains [103]. The soluble isoforms lack
all the protein domains that are encoded after exon 13 in membrane-bound VEGFR1: the seventh
immunoglobulin-like extracellular domain, the membrane-anchoring region, the juxtamembrane domain
and the intracellular signaling tyrosine kinase domains [103]. This enables the soluble isoforms to
have retained affinity for VEGF-A ligands, neuropilin-1 (NRP-1) co-receptor and extracellular heparin
sulphate proteoglycans, but prevents signal transduction. In essence, sVEGFR1 isoforms trap VEGF-A
and form inert heterodimers with VEGF receptors [39], which has caused them to be regarded as potent
anti-angiogenic factors. Investigations into the mechanisms that control the splicing of VEGFR1 have
been conducted, and numerous studies have provided evidence that hnRNP D plays a role in the
regulation of sVEGFR1-i13. One such study executed in human dermal microvascular endothelial cells
(HMVEC) unearthed two sequences within intron 13 that are responsible for the premature poly(A) signal
found in sVEGFR1, and proposed that hnRNP D binds to an A-and-U-rich-element (AURE) sequence
(AUUUA) located in intron 13 downstream of the sVEGFR1 processing site [104]. Indeed, overexpression
of hnRNP D was shown to significantly decrease the sVEGFR1/mVEGFR1 (membrane-bound VEGFR1)
ratio [104]. However, a later study conducted in human macrophage-like U937 cells provided evidence
that hnRNP D increases the expression of sVEGF1 mRNA with the use of peptides that were modelled
on the regulatory domain of hnRNP D [105]. Furthermore, this finding was strengthened by the
peptide-mediated suppressed expression of VEGF-A [105]. This discrepancy in the role of hnRNP D in
VEGFR1 splicing regulation could be due to a cell type-specific effect and/or additional modifications,
such as the altered expression of other factors yet to be uncovered as being involved in the alternative
splicing of VEGFR1. In addition, regulation of splicing events, particularly of genes that are of particular
importance, can be very complicated with many molecules involved, and so it could be that there
are other molecular mechanisms taking place that override the effect of hnRNP D. Indeed, there has
been evidence of other molecules and pathways that regulate the expression of sVEGFR1-i13. Studies
conducted in endothelial cells have revealed that the U2A65 splicing factor is implicated in the positive
regulation of sVEGFR1-i13 [106], whereas JuMonJi Domain containing protein-6 (JMJD6) and NOTCH1
have been shown to be negative modulators of the isoform [106,107]. Moreover, a recent study conducted
in squamous lung carcinoma cells has shown evidence for a more accomplished mechanism, whereby
VEGF-A165 promotes the expression of SOX2, which directly binds to the promoter of SRSF2 and induces
transcription [101]. The SRSF2 splice factor promotes splicing of VEGFR1 towards the sVEGFR1-i13
isoform [101].
3.3. Neuropilins (NRPs)
NRPs are expressed in many distinct cell types, including neurons, blood vessels and immune
cells [108]. NRPs are transmembrane co-receptors that function in both VEGF signalling (through
dimerization with VEGFR2) and semaphorin/plexin signalling, which implicate NRPs in both
angiogenesis and lymphangiogenesis, and neuronal tissue pattern development, respectively [109].
For the basis of this review, the role of NRPs in axonal development will be kept brief, as this subject
matter is beyond the scope of this review. However, it can be noted that the semaphorin-3 (SEMA3)
family of glycoproteins binds to NRP receptors to facilitate axonal guidance.
The structure of NRPs consists of various domains with different functions. The a1 and a2 domains
are involved in binding to SEMA3, and the b1 and b2 domains are required for the binding of VEGF-A;
in particular, VEGF-A165, VEGF-A121 and VEGF-A189 have been shown to bind to NRP1 [108]. In fact,
VEGF-A165 has been shown to be paramount for the complex formation between VEGFR2 and NRP1 [110].
VEGF-A165 can also bind to NRP2, however, with a 50-fold less than NRP1 [111]. Interestingly, exon 8
of VEGF-A has been shown to be crucial for binding to NRPs, and consequently VEGF165b has been
shown to be unable to bind to NRPs [112]. In addition to VEGF-A, the b1 and b2 domains of NRP1 have
also been shown to bind to other angiogenic-associated factors, including: VEGF-B, VEGF-C, VEGF-D,
placental growth factor-2 (PLGF2), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs),
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and transforming growth factor beta 1 (TGFβ1) [108], which further corroborates that NRP1 plays a key
role in angiogenesis.
NRP1 mRNA consists of 17 exons and to date, six alternatively spliced isoforms of NRP1 have
been discovered. The first to be discovered were s11NRP1 and s12NRP1, which are composed of the first
11 and 12 exons of NRP1, respectively [40,113]. An additional two more isoforms were later discovered:
sIIINRP1 and sIVNRP1. sIIINRP1 is formed from exons 1-9 and exon 12, with cassette exon skipping of
exons 10 and 11 [114]. The structure of sivNRP1 is similar to that of sIIINRP1, however, it also retains
exon 10 [114]. All four of these isoforms are soluble and do not contain the C-terminal transmembrane
and cytoplasmic domains. The resulting proteins formed are able to sequester NRP1 binding factors,
but are unable to transmit signals, and therefore act as antagonists of NRP1 signalling [40]. Hence,
these soluble isoforms of NRP1 have been associated with anti-angiogenic and anti-tumourigenic
functions. Another splice variant of NRP1, named NRP1-∆E16, is formed by the skipping of exon 16
and the addition of an arginine (AAG) [41]. Not much is documented on this isoform, as it was not
found to have any functional differences to full length NRP1.
More recently, a further splice isoform of NRP1, NRP-1∆7, was discovered [42]. This isoform is
formed by the deletion of just seven amino acids in exon 11 caused by the utilization of an alternative
donor site located 21 bases upstream of the conventional splice site (Figure 4A). The seven amino acids
that are deleted in NRP1-∆7 omit a coding sequence that contains two aspartic residues that are located
two residues downstream of the glycosylation site and are required for efficient glycosylation [115].
Glycosylation is a post translational modification that can alter the structure and function of a protein.
NRP1 is reported to be glycosylated at Serine-612, whereby long chains of oligosaccharides are formed.
Various different chains can assemble on NRP1, which are dependent on the cell type. For example,
in smooth muscle cells, chondroitin sulfate is added, whilst in endothelial cells heparin sulfate is
assembled on the glycosylation site of NRP1 [116]. The number and nature of the added oligosaccharide
chain(s) can modulate the function of a protein. Indeed, it has been reported that mutated Serine-612
prevents glycosylation at the site, increased cell invasion in human glioblastoma cells [117] and reduced
fibronectin fibrillation in a human hepatic cell line [118]. Further studies conducted in modified prostate
(PC3) and breast (MDA-MB-231) cancer cells that expressed either recombinant full length NRP1 or
NRP1-∆7, showed that NRP1-∆7 has anti-tumorigenic properties, including decreased proliferation,
migration and anchorage-dependent growth whilst the overexpression of full length NRP1 had the
opposite effect [42]. Therefore, NRP1-∆7 is considered to function in the inhibition of angiogenesis and
tumorigenesis and could have therapeutic potential.
NRP2 functions in lymphangiogenesis through dimerization with VEGFR3 and activation by
VEGF-C [119]. Indeed, NRP2 knockout mice presented with impaired lymphangiogenesis [120]. In addition,
NRP2 has been implicated in tumour metastasis. This was shown using a monoclonal antibody to inhibit
VEGF-C binding to NRP2, which in turn decreased metastasis [121]. Recently, a new splice isoform of
NRP2 named s9NRP2 has been discovered and is thought to antagonize VEGF-C/NRP2 signalling [122].
The isoform is formed from the retention of an intron between exons 9 and 10 that encodes a premature
stop codon in the b2 domain. This results in an unpaired cysteine residue that forms a disulphide bridge
with an unpaired cysteine from another s9NRP2-producing dimer. There has been evidence to show that
s9NRP2 inhibits the binding of VEGF-C to NRP2, however, with no effect on the interaction of VEGF-C to
VEGFR-3 [122]. Further research is required to establish whether the isoform also inhibits the formation
of metastasis.
3.4. Fibroblast Growth Factor Receptors (FGFRs)
There are at least five types of FGFRs named FGFR 1–5 [123]; FGFR 1-3 have a similar structure,
whereas FGFR4 lacks the transmembrane and intracytoplasmic domains. FGFR5 and an additional
receptor have also been proposed, designated as FGFR6 [124]. FGFRs have the same protein structure
that is generally found in receptor tyrosine kinases and are involved in the regulation of key biological
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cellular processes, such as proliferation, differentiation, migration and survival [125]. There are a number
of different types of alternatively spliced isoforms that can arise in FGFRs, which will be discussed below.
The most described alternative splicing event in the literature is generated from the use of
alternative exons in the c-terminus of IgIII of FGFRs1-3 [43]. The IgIII domain is comprised of three
domains: IIIa, IIIb and IIIc, which are encoded by exons 7–9, respectively. The alternative use of exons
8 and 9 form the IIIb and IIIc isoforms for FGFR1-3 (Figure 4A), which have different ligand affinities
and tissue specificities. i.e., the IIIb isoform is predominantly found in the epithelial tissues, whereas
the IIIc isoform is expressed in the mesenchymal tissues. The regulation of this splicing switch is
therefore strongly implicated in epithelial-mesenchymal-transition (EMT). A number of RBPs have
been implicated in the regulation of splicing of the c-terminus of IgIII. ESRP1 and ESRP2 promote the
expression of the IIIb isoform, and hnRNP F/H, K and forkhead box-2 (FOX-2) silence the IIIc isoform.
On the other hand, hnRNP A1 and PTB are associated with silencing of IIIb [126]. Furthermore, hnRNP
M has been shown to bind to ISE/ISS-3 of FGFR2 and promote exon IIIc skipping [127]. Another more
detailed splicing mechanism for the regulation of IIIb and IIIc splicing involves RBM4 and nPTB [128].
In short, RBM4 promotes the expression of the IIIb isoform, whereas nPTB induces exon IIIc inclusion.
Interestingly, the RBM4 splice factor is also implicated in promoting exon 10 skipping of PTB to produce
the nPTB splice variant [128], and this therefore shows the extent that splicing mechanisms are tightly
controlled. The splicing regulation of FGFR2 is a prime example of how RNA-binding proteins work
in combination to bring about a splicing profile. A mesenchymal phenotype is linked to the promotion
of tumorigenesis, and aberrant expression of the IIIb and IIIc isoforms has been documented in animal
models of bladder cancer and epithelial cell tumours [129–131]. Furthermore, elevated expression
of both the IIIc and IIIb isoforms has been shown in a variety of cancerous cells and tissues [43].
However, expression of FGFR-2 IIIb in oesophageal and colorectal cancers was associated with better
differentiation and decreased expression of the isoform correlated with proliferation, invasion and
poor prognosis [44]. Furthermore, the loss of the IIIb isoform and increase in IIIc expression has been
associated with a more aggressive cancer phenotype [44]. In light of the above, it could be concluded
that the IIIc isoform is a tumour promoter, and IIIb acts as a tumour suppressor; however, increased
expression of FGFR-2 IIIb has also been linked to cell transformation and tumour progression in some
cancers, and so the precise role of FGFR-2 IIIb in cancers remains controversial [44]. For example,
in gastric cells, FGFR-2 IIIb expression was associated with cellular invasion of the gastric wall; however,
decreased expression of FGFR-2 IIIb in gastric cells was also linked to proliferation, invasion and poor
prognosis [44]. Furthermore, FGF-7 and FGFR-2 IIIb have been implicated in tumour angiogenesis
through inducing an increase in VEGF-A expression in colorectal and pancreatic cancers [132,133].
This is a prime example of how there is a lot of cross-talk between different arms of angiogenesis
signalling, and therefore associates FGF-7 and the FGFR-2 IIIb isoform in particular in the promotion
of angiogenesis.
The next splicing event of FGFRs that will be discussed is the inclusion or exclusion of exons that
encode the IgI and acid box domains, which are formed from exons three and four respectively in
FGFRs 1–3, and exons two and three respectively in FGFR4 [134,135]. Both domains are involved in
the auto-inhibition of FGFRs [43]. In fact, isoforms that do not contain these domains have heparin
sulfate proteoglycan attachments, which strengthens the affinity for binding to ligands and enhances
signalling transduction of FGFRs [136]. The excision of the IgI domain produces an isoform that has
two loops in the extracellular domain (formed by IgII and IgIII), named FGFRβ, whereas the inclusion
of the exon produces FGFRα, which has three loops in the extracellular domain [137]. Therefore,
the FGFRβ isoforms, which do not contain the auto-inhibitory IgI domain, have a higher affinity for
FGFs and enhanced signalling [45,46]. Indeed, FGFR-1β has been shown to increase proliferation
through having a stronger affinity for FGF1 and displaying augmented signalling [43]. Furthermore,
an elevation in the expression ratio of FGFR1β:FGFR1α has been linked to tumour progression [43].
Recently, the polypyrimidine tract-binding protein 1 (PTPBP1) splicing repressor has been implicated
in the regulation of alternative splicing of FGFR1α and FGFR1β. The study conducted in breast cancer
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cells revealed that PTBP1 represses the splicing of FGFR1β [138]. However, PTBP1 has also been
reported to induce α exon deletion through the binding of intronic splicing silencer sequences that
flank the α exon resulting in the positive regulation of FGFR1β [139]. Therefore, further investigation is
required to clarify the precise role of PTBP1 in the regulation of FGFR1α/FGFR1β splicing. In addition,
the SRSF6 splicing factor has been implicated in the exclusion of the α exon, which has been attributed
to the presence of two exonic splicing enhancers located in the α exon, which can be bound by SRSF6
to facilitate the exclusion of the α exon [140]. Indeed, knock downs of SRSF6 resulted in the increased
expression of FGFR1α [140].
Another class of isoforms are formed from the skipping of exons 8, 9 and 10. This region encodes
the transmembrane domain, which is responsible for anchoring FGFRs to the cellular membrane.
Therefore, this alternative splicing event produces soluble FGFR receptors, which can be found in
other locations in the cell other than the cell membrane. For example, a soluble isoform of FGFR3,
which arises from the deletion of exon 8 as well as exon 7, has been shown to be predominantly found
in the nucleus of breast epithelial cells [45]. Although the precise functions of these isoforms are yet
to be determined and may be diverse depending on the splicing events that exist in other regions of
the sequence, it can be proposed that many of the soluble isoforms act as an antagonist through the
binding of ligands without the activation of signal transduction, which is true of other soluble tyrosine
kinase receptors. Indeed, a soluble isoform of FGFR4 has been shown to diminish FGF1 signalling in
human Michigan Cancer Foundation-7 (MCF-7) breast cancer cells [43].
A further group of FGFR splice isoforms arise from the inclusion of differing carboxy-terminal
sequences, termed C1, C2 and C3. The distinct sequences produce proteins that have differential
retention of tyrosine residues, which function as docking sites for cytoplasmic signalling proteins and
are also involved in autophosphorylation of the receptor [47]. The C3 variant has been documented to
be the most transforming of the isoforms when compared to C2, which has moderate transforming
activity, and C1 which has weak activity. The increased transforming activity elicited by the C3 isoform
strongly suggests a role for these variants in oncogenesis. In support of this, elevated expression of the
C3 isoform has been detected in gastric cell lines and in human breast cancer cell lines [47].
Another type of splice isoform that arises in FGFRs is produced via the inclusion or deletion
of six nucleotides (GTAACA), known as the VT motif which codes for two amino acids (valine and
threonine) in the juxtamembrane region of FGFR1-3 [141]. The inclusion or exclusion of the VT motif
affects the signalling capability of the receptor, as the exclusion of the VT motif prevents the binding
of effector molecules. In fact, isoforms that contain the VT motif are able to activate the Ras/MAPK
signalling pathway [48]. Therefore, as one of the major downstream pathways of FGFR is affected,
it has been postulated that the absence of the VT motif could have major implications for the function
of FGFR. However, other signalling pathways that rely on receptor kinase activity for activation remain
unaffected by the exclusion of the VT motif, such as the downstream effectors of phospholipase C-γ
(PLCγ) [141]. Therefore, the inclusion or exclusion of the VT motif may selectively activate different
signalling mechanisms in varied cell types.
3.5. Vasohibins
Vasohibin-1 is a negative regulator of angiogenesis that is typically expressed in endothelial cells
and is regulated by VEGF-A and FGF-2 [51]. Whilst vasohibin-1 inhibits VEGF-stimulated angiogenesis,
it does not inhibit the phosphorylation and subsequent activation of VEGFRs; however, vasohibin-1
does inhibit FGF-2-activated angiogenesis [142]. In fact, it was also shown that vasohibin-1 is activated
by VEGFR-2 and its downstream effector, protein kinase C-δ (PKC-δ), in endothelial cells resulting in the
inhibition of angiogenesis [51]. PKC-δ is also involved in the induction of vasohibin-1 by FGF-2, which
further implies that this factor is imperative to the regulation of vasohibin-1 expression [51]. Vasohibin-1
has also been shown to regulate the hypoxia inducible factor-1α (HIF-1α) pathway through inducing
the degradation of HIF-1α by prolyl hydroxylase, which suggests that hypoxia and vasohibin-1 act in
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concert to regulate one another [143]. Therefore, the expression of vasohibin-1 is highly regulated in
a number of ways.
Later, another gene which shared 52.5% homology with vasohibin-1 was discovered and designated
vasohibin-2 [144]. Human vasohibin-2 was shown to also exert anti-angiogenic activity; however,
unlike vasohibin-1, vasohibin-2 was not found to induce VEGF–A or FGF-2. Furthermore, vasohibin-2
is not regulated by cytokines or growth factors [144]. However, a microRNA (mir-200b) has been shown
to target and therefore diminish the expression of vasohibin-2 [144,145].
Studies of multiple collections of microarray data has revealed that the two genes have entirely
different profiles of co-expression with other genes, suggesting that vasohibin-1 and vasohibin-2
have distinct functions [144]. In accordance, vasohibin-1 is expressed in endothelial cells of newly
formed blood vessels behind the sprouting front and acts to halt angiogenesis, whereas vasohibin-2 is
expressed in mononuclear cells that help form the sprout and promotes angiogenesis [144]. Indeed,
vasohibin-2 has been linked to tumour growth through the stimulation of angiogenesis [145,146],
whereas vasohibin-1 has been shown to be an effective treatment for angiogenesis in various animal
models, including diabetic nephropathy, pulmonary fibrosis, ocular angiogenesis and cancers [144].
The two main isoforms of vasohibin-1 that have been documented in the literature are the 365aa
isoform, known as vasohibin-1A (VASH1A) formed by seven exons, and the 204aa isoform, known as
vasohibin-1B (VASH1B), which consists of four exons [50] (Figure 4A). The proteins generated from
these isoforms have the same N-terminus, which contains a nuclear localisation signal, but a different
C-terminus, which is thought to be important for anti-angiogenic activity [49]. Interestingly, a study
of in vivo blood vessel growth conducted in chicken chorioallantoic membrane showed that whilst
VASH1A did not inhibit vessel growth, the vessels were shown to be irregular; however, VASH1B
inhibited vessel growth strongly [49]. Furthermore, in vitro studies of angiogenesis showed that
VASH1B inhibited endothelial cell growth, migration and tube formation [49]. VASH1A on the other
hand, only had a significant effect on migration in vitro; in fact VASH1A significantly increased
endothelial cell migration [49]. Moreover, the VASH1B isoform was shown to induce apoptosis
in endothelial and fibroblast cells, whereas VASH1A was not shown to only induce apoptosis in
fibroblasts [49]. A later study was able to explain the differences in functions exerted by the two
vasohibin isoforms [50]. It was shown that VASH1A promoted normalisation of abnormal tumour
blood vessels, whereas VASH1B induced autophagy, which promotes either cellular survival or
cellular death in order to maintain homeostasis. Therefore, the same group investigated the effects
of combination treatments that included both isoforms and found that the combination treatments
had the highest anti-tumour effects with marked vascular normalisation when compared to treatment
with either isoform alone [50]. Therefore, combination treatments with VASH1A and VASH1B may be
useful in antiangiogenic treatments, as the existing vasculature can be normalised by VASH1A and
pruned by VASH1B.
The alternative splicing of vasohibin-2 is less documented. Vasohibin-2 contains 11 exons which
are alternatively spliced to produce transcripts that are: 355aa, 311aa, 290aa, 156aa, 117aa and 104aa.
The largest isoform (355aa) has been shown to be predominantly expressed in HUVEC cells, and the
290aa splice variant has been shown to have antiangiogenic activity [51]. The function of the other
isoforms have not yet been classified. As mentioned in the beginning of this section, vasohibin-2 was
found to be involved in the stimulation of angiogenesis and is highly expressed at the sprouting front.
The drive of angiogenesis by vasohibin-2 was linked to high expression of the protein in mononuclear
cells at the sprouting front, whereas anti-angiogenic activity of vasohibin-2 was identified in endothelial
cells. This suggests that perhaps vasohibin-2 has distinct functions in different cell types. Another
reason for this discrepancy could be that splice isoforms of vasohibin-2 whose function has not yet
been determined could have opposing functions.
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3.6. Hypoxia Inducible Factor-α (HIF-α)
Hypoxia is a feature of many diseases, such as cancers whereby inadequate vasculature causes
pockets of low oxygen. This exerts a pro-apoptotic response in some cancer cells [147], as they do not
receive the oxygen they require for survival. Therefore, hypoxia elicits various responses including
the promotion of angiogenesis in order to provide cells with the oxygen that they need. The most
established signalling pathway that is induced by hypoxia is the hypoxia inducible factor-α (HIF-α)
pathway. In short, HIF-α forms a dimer with HIF-β, also known as aryl hydrocarbon receptor nuclear
translocator (ARNT), which then binds to HIF-response cis-elements to facilitate the transcription of
target genes, including VEGF-A. However, in normoxic conditions, prolyl hydroxylases (PHD) interacts
with HIF-α, allowing the von Hippel-Lindau (VHL) protein to bind and target the degradation of
HIF-α by the proteasome thereby preventing any transcription of HIF-targeted genes [8]. There are
three homologous of HIF-α and HIF-β that are designated HIF-1α and HIF-1β, HIF-2α and HIF-2β,
and HIF-3α and HIF-3β [55]. The HIF-1α and HIF-2α subunits share similar domain assemblies and
undergo proteolytic regulation [55]. However, HIF-3α has been generally considered as a negative
regulator of HIF-1α, but not HIF-2α [148]. The most studied of these are the HIF-1α subunits.
Several splice isoforms of HIF-1αhave been described in the literature, which arise from cassette exon
skipping: HIF-1α ∆11, HIF-1α ∆12, HIF-1α ∆11&12, HIF-1α ∆14, and HIF-1α417 [53,54,149]. The splicing
scheme for HIF-1α ∆14is shown in Figure 4A. Most of these isoforms lack exons that encode parts of the
oxygen-dependent degradation domain which is targeted by prolyl hydroxylases (PHDs), or C-terminus
transactivation domains, which are required for transcription of HIF-targeted genes [149]. As most of
these isoforms have reduced or completely abolished HIF function and have a dampening effect on the
initiation of HIF-activated transcription of target genes, it is therefore predicted that these isoforms are
stable in normoxia in order to maintain negative regulation of HIF signalling in the presence of oxygen.
In accordance with this, a study found that the HIF-1α ∆14 isoform is expressed at higher levels than
the canonical isoform during normoxia [54]. During hypoxia, however, both the canonical isoform of
HIF-1α and HIF-1α ∆14 were able to dimerise with HIF-1β and activate the VEGF-A promoter [54].
However, HIF-1α ∆14 was shown to have a three-fold less potency than the canonical form of HIF-1α [54].
Furthermore, HIF-1α ∆12 and HIF-1α ∆11&12 both block the dimerization of HIF-1α and HIF-1β
by isolating HIF-1β to the cytoplasm [53]. Therefore, these two isoforms act as dominant-negative
regulators of HIF-1 transcription. The skipping of exon 10 produces the HIF-1α417 splice variant, which
causes a frame-shift and results in a truncated protein of 417 amino acids in length [53]. The resultant
protein lacks a transactivation domain and so was thought not to act as a principal transcription factor.
However, further experiments showed that the splice variant amplified HIF-1β-mediated transcription
of the erythropoietin (EPO) reporter gene [53], which shows another mechanism in which HIF target
genes are transcribed. In contrast to the other isoforms, there is evidence to show that HIF-1α ∆11
promotes tumorigenesis through the enhancement of HIF-1 activity. Indeed, overexpression of HIF-1α
∆11 increased tumour growth in vivo [52]. An additional alternative splicing event involves the insertion
of three bases (TAG) between exons 1 and 2 of HIF-1α, which substitutes an asparagine in place of
a lysine and inserts an additional arginine [44]. This significance of this isoform remains to be elucidated.
Another splice variant of HIF-1α arises from an alternative upstream translational start site, which
produces a protein that has an N-terminus that is 24 amino acids longer than canonical HIF-1α named
HIF-1α Alt1[150].
HIF-3α, the dominant negative regulator of HIF-1α, has also been reported to undergo alternative
splicing [47,151]. The most established alternative splice isoform of HIF-3α is inhibitory Per/Arnt/Sim
(IPAS), which is formed through multiple alternative splicing events and is inducible by hypoxia
(Figure 4B). IPAS shares exons 2, 4 and 5 with the canonical HIF-3α; however, IPAS also contains
an alternative exon upstream of exon 1 (designated 1a), as well as an additional exon before exon 4
(designated exon 4a) and exon 16. The use of alternative splice sites in exons 3 and 6 are also present in
IPAS [151]. The inclusion of exon 4a, together with the use of the alternative 3′ splice site of exon 3,
results in a frame shift. The resultant protein lacks transactivation domains and so cannot initiate
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transcription [53]. IPAS dimerises with HIF-α subunits, thereby preventing the transcription of HIF
target genes, such as VEGF-A [55]. Indeed, in cornea epithelium, IPAS was found to negatively regulate
VEGF-A gene expression and therefore, was shown to indirectly dampen angiogenesis [56]. Another
splice variant of HIF-3α that is generated by the inclusion of intron 7 and known as HIF-3α4 is reported
to be similar to IPAS [55,152]. HIF-3α4 forms a complex with HIF-1α, which prevents the binding of
HIF to hypoxia response elements, and subsequent transcription of target HIF genes. Indeed, inducible
HIF-3α4 was shown to hamper angiogenesis and proliferation [55].
3.7. Angiopoietin
Angiopoietins and Tie receptors are involved in endothelial cell survival and vascular maturation.
There are four members of the angiopoietin family, designated angiopoietin 1–4 (Ang-1-4) [153].
Ang-1 and Ang-2 are the most characterised in the literature. They share around 60% homology
and both bind to the same site of the TEK receptor tyrosine kinase-2 (Tie-2) receptor with similar
affinity [153]. Ang-1 is expressed by smooth muscle cells and perivascular cells, whereas, Ang-2 is
primarily expressed by endothelial cells and is stored in Weibel-Palade bodies within the cells [153,154].
Upon cytokine activation of the endothelium, Ang-2 is released from the Weibel-Palade bodies through
a neuroligin-2-dependent mechanism and binds to the Tie-2 receptor [155]. Originally, it was thought
that Ang-1 acted as an agonist of the Tie-2 receptor and Ang-2 was an antagonist of the Tie-2 receptor,
as it has been shown to bind to Tie-2 but did not induce autophosphorylation of the receptor [156].
However, further investigations have shown that Ang-2 can also act as an agonist of the Tie-2 receptor.
A range of solutions have been proposed to explain the contrasting functions assigned to Ang-2, such as
cell type-specific effects, Ang-2 stimulation duration, the presence of co-receptors (e.g., Tie-1), and
the presence or absence of other molecules [153]. Indeed, it has been shown in chicken testis that
Ang-2 induces angiogenesis in the presence of VEGF-A, whereas in the absence of VEGF-A, Ang-2 was
associated with vascular regression [58]. Alternative spliced variants of Ang-2 with varied functions
could also account for the discrepancies for functional assignment of Ang-2.
The first discovered isoform was the Ang-2B variant, which was detected in chicken testis, and
arises from the inclusion of exon 1B instead of exon 1 [58]. The study found that the canonical isoform
(assigned Ang-2A) had a higher expression than the alternatively spliced Ang-2B isoform in immature
testis and fully regressed testis, whereas the Ang-2B isoform was expressed more highly in adult
quiescent testis than the Ang-2A isoform. Therefore, the study theorised that although a precise
function could not be assigned to the Ang-2B isoform, there was an indication that Ang-2A may be
involved in vascular remodelling in immature testis and fully regressed testis, whereas the Ang-2B
isoform may be involved in inactivating the vasculature in quiescent testis [58]. Soon after the discovery
of the Ang-2B isoform, another splice variant was discovered in humans, which arises from the skipping
of exon 2, named Ang-2443 (and also known as Ang-2C) [59,157,158] (Figure 4A). In likeness to Ang-2,
the splice variant was also shown to bind to Tie-2 but did not stimulate Tie-2 phosphorylation, thereby
acting as an antagonist of Tie-2 signalling activation [59]. Therefore, there is an indication that it
may be involved in the regulation of angiogenesis. Furthermore, moderate Ang-2443 expression was
also found in the C33A and CaSki cervical carcinoma cell lines and the isoform was also detected
in primary tumour tissues, hemangioma and breast carcinoma, suggesting that the isoform may be
involved in tumorigenesis of non-endothelial tumour cells [59]. Moreover, high expression of the
isoform was detected during early macrophage differentiation, suggesting a role in the regulation of
inflammatory processes [59]. Ang-1 has four reported splice variants, which are named according to
their size; however, the type of splicing that generates each of them is not clear. Albeit, there has been
some research into the function of the isoforms. Both 1.5 kb (full-length Ang-1) and 1.3 kb bind to Tie-2
and induce its autophosphorylation, whereas the 0.9 kb and 0.7 kb splice variants also bind to the Tie
receptor but are unable to induce its autophosphorylation [57]. Therefore, the 0.9kb and 0.7kb splice
variants act as inhibitors of Ang-1 signalling.
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Several studies have implicated Ang-1 and Ang-2 in the promotion and inhibition of
tumourigenesis [159–162]. There could be a few reasons for the discrepancies in tumorigenic function of
Ang-1 and Ang-2, including: the effects of Ang-1 or Ang-2 may be cell-type specific; both angiopoietins
may be increased and so determining the function of one may be construed as the function exerted by
the other highly expressed angiopoietin [153]; or the variation could be due to differential expression
of Ang-1 or Ang-2 splice variants.
4. Manipulation of Alternative Splicing as a Potential Therapy for Angiogenic Associated
Diseases
Many genes are alternatively spliced to produce splice isoforms that act as negative regulators.
Therefore, there is an interest in exploiting this system in order to switch splicing profiles in disease to
favour certain isoforms for therapeutic benefit. In other words, the general idea is to downregulate
the expression of disease-causing isoforms to favour the expression of isoforms that do not promote
disease progression.
One of the most common methods for achieving this is through the use of splice switching
oligonucleotides (SSOs), which function through binding to cis-elements, and inhibiting the binding of
splice factors at a specific splice site. In 2016, the FDA approved the first exon skipping SSO to be used
in humans known as eteplirsen for the treatment of Duchenne Muscular Dystrophy (DMD) [163,164].
Another method of altering splicing profiles is through the manipulation of molecular mechanisms
that regulate the splicing of a given gene by using small molecule compounds. An example of this is
SPHINX, which is a small molecular compound that inhibits the SRPK1 splice factor kinase. SRPK1
phosphorylates and activates the SRSF1 splice factor, which is involved in the induction of the
VEGF-Axxx pro-angiogenic isoform. However, when SRPK1 is inhibited by SPHINX, SRSF1 is not
activated and the splicing profile is switched to favour the anti-angiogenic VEGF-Axxxb splice isoform.
SPHINX has been shown to successfully reduce angiogenesis in several mouse models, including:
ocular neovascularization [165], melanoma xenografts [166] and orthotopic prostate cancer [167].
Recently, a more potent form of SPHINX has been developed, named SPHINX31, which has a reported
IC50 of 6nM [168]. In a similar thread, recently, another group uncovered the SRPK1-inhibitory function
of an existent FDA-approved drug originally described as an ALK1 inhibitor called Alectinib, which
had a half maximal inhibitory concentration (IC50) for SRPK1 kinase activity of 11nM [169]. Therefore,
the next few years should yield some exciting findings and possible options for splicing-targeted
angiogenic therapy.
5. Conclusions
Angiogenesis is a complicated process that is regulated by a variety of factors, and alternative
splicing of angiogenic genes adds another layer of regulation to the angiogenic process. There are many
splice isoforms that have a negative effect compared to the canonical isoform, which allows for careful
regulation of the complicated angiogenic process. The importance of careful regulation is shown in
pathologies whereby angiogenesis is dys-regulated, such as cancer, diabetic nephropathy, rheumatoid
arthritis and endometriosis. Indeed, there have been many studies that have identified aberrant
expression of angiogenic splice isoforms in cancers as described in this review. It is hoped that future
studies will uncover more of the mechanisms associated with the generation of the splice isoforms
mentioned for therapeutic benefit. Furthermore, the identification of additional splice isoforms of
angiogenic-associated genes will allow more scope for the development of therapeutic drugs.
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